自然杂志 ›› 2025, Vol. 47 ›› Issue (6): 419-426.doi: 10.3969/j.issn.0253-9608.2025.06.001

• 特约专稿 •    下一篇

紫杉醇生物合成研究进展——抗癌明星药物的幕后工程

张逸雪,李艺柔,蒋彬,张晓林,闫建斌
  

  1. 中国农业科学院农业基因组研究所,广东 深圳 518124
  • 收稿日期:2015-11-09 出版日期:2025-12-25 发布日期:2025-12-17
  • 基金资助:
    国家重点研发计划(2023YFA0915800)

Advances in the biosynthesis of paclitaxel: The engineering behind a star anti-cancer drug

ZHANG Yixue, LI Yirou, JIANG Bin, ZHANG Xiaolin, YAN Jianbin   

  1. Agricultural Genomics Institute at Shenzhen, Chinese Academy of Agricultural Sciences, Shenzhen 518124, Guangdong Province, China
  • Received:2015-11-09 Online:2025-12-25 Published:2025-12-17

摘要:

紫杉醇,一种从红豆杉属植物中提取的二萜类天然产物,已成为临床应用广泛且市场需求巨大的植物源抗肿瘤药物。随着红豆杉基因组解析及合成生物学的快速发展,近年来,紫杉醇生物合成路径的关键酶鉴定与异源重构取得重要进展,突破了紫杉醇生物合成研究的关键瓶颈,为基于生物合成途径实现紫杉醇的绿色、可持续生产奠定重要基础。本文针对红豆杉基因组学分析、紫杉醇合成策略以及紫杉醇异源重构的相关研究进展进行综述。

关键词:

Abstract:

Paclitaxel, a diterpenoid natural product extracted from Taxus plants, has been a widely used and highly demanded plant based anti-tumor drug in clinical practice. With the rapid development of Taxus genome analysis and synthetic biology, in recent years, significant progress has been made in the identification and heterologous reconstruction of key enzymes in the paclitaxel biosynthesis pathway, breaking through the key bottlenecks in paclitaxel biosynthesis research and laying an important foundation for the green and sustainable production of paclitaxel based on the biosynthesis pathway. This article reviews the research progress on the genomic analysis of Taxus, the synthesis strategy of paclitaxel, and the heterologous reconstruction of paclitaxel.